How to buy Atea Pharmaceuticals stock (Atea Pharmaceuticals)

Atea Pharmaceuticals is a biotechnology business based in the US. Atea Pharmaceuticals shares (AVIR) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.24 – an increase of 2.53% over the previous week. Atea Pharmaceuticals employs 75 staff and has a trailing 12-month revenue of around $192.2 million.

Our top picks for where to buy Atea Pharmaceuticals Inc stock

Buy Atea Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Atea Pharmaceuticals stock price (NASDAQ: AVIR)

Use our graph to track the performance of AVIR stocks over time.

Atea Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$3.24
52-week range	$2.75 - $4.60
50-day moving average more info button	$3.33
200-day moving average more info button	$3.61
Wall St. target price	$7.40
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.07

Is it a good time to buy Atea Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Atea Pharmaceuticals price performance over time

Historical closes compared with the close of $3.19 from 2024-12-20

1 week (2024-12-17)	0.95%
1 month (2024-11-22)	-5.34%
3 months (2024-09-24)	-8.86%
6 months (2024-06-24)	-8.60%

1 year (2023-12-22)	1.27%
2 years (2022-12-23)	-30.50%
3 years (2021-12-23)	9.11
5 years (2019-12-20)	N/A

Atea Pharmaceuticals financials

Revenue TTM	$192.2 million
Gross profit TTM	$-81,936,000
Return on assets TTM	-14.25%
Return on equity TTM	-33.46%
Profit margin	0%
Book value	$5.43
Market Capitalization more info button	$266.9 million

TTM: trailing 12 months

Atea Pharmaceuticals share dividends

We're not expecting Atea Pharmaceuticals to pay a dividend over the next 12 months.

You may also wish to consider:

• Gilead Sciences (GILD.US) (3.4% forward annual dividend yield)
• GlaxoSmithKline PLC ADR (GSK.US) (4.64% forward annual dividend yield)
• Novartis AG ADR (NVS.US) (3.86% forward annual dividend yield)

Atea Pharmaceuticals share price volatility

Over the last 12 months, Atea Pharmaceuticals's shares have ranged in value from as little as $2.75 up to $4.6. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Atea Pharmaceuticals's is 0.17. This would suggest that Atea Pharmaceuticals's shares are less volatile than average (for this exchange).

To put Atea Pharmaceuticals's beta into context you can compare it against those of similar companies.

• Gilead Sciences (GILD.US): 0.192
• GlaxoSmithKline PLC ADR (GSK.US): 0.33
• Novartis AG ADR (NVS.US): 0.505

Atea Pharmaceuticals overview

Atea Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Frequently asked questions

null
What percentage of Atea Pharmaceuticals is owned by insiders or institutions?
Currently 9.566% of Atea Pharmaceuticals shares are held by insiders and 71.145% by institutions. How many people work for Atea Pharmaceuticals?
Latest data suggests 75 work at Atea Pharmaceuticals. When does the fiscal year end for Atea Pharmaceuticals?
Atea Pharmaceuticals's fiscal year ends in December. Where is Atea Pharmaceuticals based?
Atea Pharmaceuticals's address is: 225 Franklin Street, Boston, MA, United States, 02110 What is Atea Pharmaceuticals's ISIN number?
Atea Pharmaceuticals's international securities identification number is: US04683R1068